ciao Amedeo , ciao Lorociu , io personalmente penso che ci potrebbe stare un altro up a breve.....ma non entro per il bene degli azionisti cell
Ciao...........Sergio................
Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
PR Newswire
Cell Therapeutics, Inc. 1 hour ago
SEATTLE, Dec. 18, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that CTI has received the remaining $5 million from Hercules Technology Growth Capital, Inc. (HTGC) available under the existing loan agreement that was established in March 2013. Further information with respect to this loan with Hercules will be available in a Current Report on Form 8-K that will be filed by CTI with the Securities and Exchange Commission.
About Cell Therapeutics, Inc.
Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit
Cell Therapeutics, Inc.: Home.
About Hercules Technology Growth Capital, Inc.
Hercules Technology Growth Capital, Inc., (HTGC) is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and energy and renewables technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $3.9 billion to over 250 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. For more information please visit
HTGC, or call 650-289-3060.
.............................................................
Form 8-K for CELL THERAPEUTICS INC
Summary of CELL THERAPEUTICS INC - Yahoo! Finance
13-Dec-2013
Change in Directors or Principal Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Compensatory Arrangements of Certain Officers.
On December 10, 2013, the Compensation Committee (the "Committee") of the Board of Directors of Cell Therapeutics, Inc. (the "Company") approved fiscal year-end cash incentive awards for 2013 for each of the Company's named executive officers currently employed with the Company in the amounts set forth below, in each case based on the achievement of certain 2013 goals and objectives of the Company and the Committee's review and subjective assessment of the performance and contributions of each of the named executive officers during 2013.
Name and Principal Position Bonus
James A. Bianco, M.D. $ 682,500
President and Chief Executive Officer
Louis A. Bianco $ 216,000
Executive Vice President, Finance and Administration
Jack W. Singer, M.D. $ 203,500
Executive Vice President, Global Medical Affairs and Translational
Medicine
Matthew Plunkett, Ph.D. $ 260,000
Executive Vice President, Corporate Development